Podcasts about consensus

In this episode of the JIMD Podcast, we explore manganese transporter disorders with Dr Karin Tuschl, Dr Suvasini Sharma and Prof John Spencer, covering clinical red flags, MRI clues, EDTA chelation, and the urgent search for safer, oral treatments for hypermanganesemia with dystonia. Consensus of Expert Opinion for the Diagnosis and Management of Hypermanganesaemia With Dystonia 1 and 2 Sherry Fang, et al https://doi.org/10.1002/jimd.70031 Removal of Toxic Metabolites—Chelation: Manganese Disorders Hendrik Vogt, et al https://doi.org/10.1002/jimd.70107

Dr. Travis Morrell, chair of Colorado Principled Physicians and a senior fellow at Do No Harm Medicine, joins me to pull back the curtain on what he calls the "medical mafia"—the intricate web of organizations led by the American Medical Association that manufactures the illusion of consensus on controversial medical practices, particularly pediatric sex trait modification.We explore how the AMA maintains its power despite only 15% of American doctors being members. The answer lies in a government-mandated monopoly: the AMA holds the copyright on CPT codes—the procedural codes every healthcare provider in the country must use to bill insurance and Medicare. This generates hundreds of millions in revenue annually, which the AMA then uses to lobby politicians, influence other medical organizations, and train activists within specialty societies to align with their positions.Travis explains how this money flows into shadow organizations like Race Forward to push diversity, equity, and inclusion initiatives that ultimately tie back to gender ideology in medicine. We discuss the physical harms of cross-sex hormones on women—including vaginal atrophy, pelvic floor dysfunction, and incontinence affecting over 95% of female patients on testosterone—and why Travis compares these effects to female genital mutilation. We also discuss what everyday people and physicians can do to push back against this institutional capture, and why speaking up—even privately—is a moral duty.Travis Morrell, MD, MPH, is a dad, husband, and physician. A lifelong learner to a fault, his postgraduate medical training in five specialty departments and medical leadership gives him a broad perspective of his profession. He is published in the top journals of multiple fields and in popular media. Dr. Morrell is a Senior Fellow at Do No Harm Medicine. He is Chair of Colorado Principled Physicians, a grassroots organization of physicians promoting evidence-based medicine and classical liberal values.The X thread mentionedX: @MorrellMDmphProtect Kids ColoradoColorado Principled PhysiciansStop the Harm Database[00:00:00] Start[00:00:46] Introducing Dr. Travis Morrell[00:09:30] The AMA's $450 Million Empire and CPT Code Monopoly[00:17:34] How the AMA Controls Other Medical Organizations[00:30:53] Who's Driving the Gender Ideology Agenda[00:44:35] Cross-Sex Hormones as Female Genital Mutilation[00:49:06] Physical Harms of Testosterone on Women[01:07:01] What Doctors and Patients Can Do[01:10:51] Why Doctors Alone Won't Save the Day[01:17:43] Compassion for Affected Kids and Families[01:18:47] Where to Find Dr. Travis MorrellROGD REPAIR Course + Community gives concerned parents instant access to over 120 lessons providing the psychological insights and communication tools you need to get through to your kid. Now featuring 24/7 personalized AI support implementing the tools with RepairBot! Use code SOMETHERAPIST2026 to take 50% off your first month.PODCOURSES: use code SOMETHERAPIST at LisaMustard.com/PodCoursesTALK TO ME: book a meeting.PRODUCTION: Looking for your own podcast producer? Visit PodsByNick.com and mention my podcast for 20% off your initial services.SUPPORT THE SHOW: subscribe, like, comment, & share or donate.Watch NO WAY BACK: The Reality of Gender-Affirming Care. Use code SOMETHERAPIST to take 20% off your order.MUSIC: Thanks to Joey Pecoraro for our song, “Half Awake,” used with gratitude & permission.ALL OTHER LINKS HERE. To support this show, please leave a rating & review on Apple, Spotify, or wherever you get your podcasts. Subscribe, like, comment & share via my YouTube channel. Or recommend this to a friend!Learn more about Do No Harm.Take $200 off your EightSleep Pod Pro Cover with code SOMETHERAPIST at EightSleep.com.Take 20% off all superfood beverages with code SOMETHERAPIST at Organifi.Check out my shop for book recommendations + wellness products.Show notes & transcript provided with the help of SwellAI.Special thanks to Joey Pecoraro for our theme song, “Half Awake,” used with gratitude and permission.Watch NO WAY BACK: The Reality of Gender-Affirming Care (our medical ethics documentary, formerly known as Affirmation Generation). Stream the film or purchase a DVD. Use code SOMETHERAPIST to take 20% off your order. Follow us on X @2022affirmation or Instagram at @affirmationgeneration.Have a question for me? Looking to go deeper and discuss these ideas with other listeners? Join my Locals community! Members get to ask questions I will respond to in exclusive, members-only livestreams, post questions for upcoming guests to answer, plus other perks TBD. ★ Support this podcast on Patreon ★

Derek Moore is joined by Shane Skinner, Mike Snyder, and yup Jay Pestrichelli makes an appearance to give our 2026 predictions. Where will markets, the economy, gold, the dollar, the fed, interest rates, bitcoin, recession, oil, bitcoin and much more plus a look back at who got 2025 right.   2026 Year End S&P 500 Index Targets VIX high for 2026 10 Year Treasury predictions Where will Bitcoin end 2026? Where will Oil, Gold, & the US Dollar End land in 2026? Outliers amongst the group and some consensus Why you shouldn't trade off these Why committing to strategies rather than trying to time markets is the way 2025 Predictions and who was right and who was wrong The challenge in trying to predict markets When will the last Fed rate change happen next year? Where do interest rates wind up landing? What about GDP and CPI Inflation forecasts for 2026?   Mentioned in this Episode   Derek Moore's book Broken Pie Chart https://amzn.to/3S8ADNT   Jay Pestrichelli's book Buy and Hedge https://amzn.to/3jQYgMt   Derek's book on public speaking Effortless Public Speaking https://amzn.to/3hL1Mag   Contact Derek derek.moore@zegainvestments.com    

In this episode of The Venture Capital Podcast, Jon Bradshaw and Peter Harris are joined by Stine Mølgaard Sørensen, Partner at Alliance VC, a Nordic early-stage fund focused on AI.Stine—an operator and repeat founder turned investor—shares how Nordic venture approaches contrarian vs consensus investing, why Scandinavia can be a powerful “safe launchpad” for startups, and what founders should consider when scaling beyond Europe. The conversation also tackles a question most investors avoid: when should a board member step down—and how do you make that change without blowing up relationships?They also discuss Alliance VC's portfolio, including 1X (humanoid robots) and Superside, plus what it takes to build real conviction early.Follow the PodcastInstagram: https://www.instagram.com/venturecapitalfm/Twitter: https://twitter.com/vcpodcastfmLinkedIn: https://www.linkedin.com/company/venturecapitalfm/Spotify: https://open.spotify.com/show/7BQimY8NJ6cr617lqtRr7N?si=ftylo2qHQiCgmT9dfloD_g&nd=1&dlsi=7b868f1b72094351Apple: https://podcasts.apple.com/us/podcast/venture-capital/id1575351789Website: https://www.venturecapital.fm/Follow Jon BradshawLinkedIn: https://www.linkedin.com/in/mrbradshaw/Instagram: https://www.instagram.com/mrjonbradshaw/Twitter: https://twitter.com/mrjonbradshawFollow Peter HarrisLinkedIn: https://www.linkedin.com/in/peterharris1Twitter: https://twitter.com/thevcstudentInstagram: https://instagram.com/shodanpeteYoutube: https://www.youtube.com/@peterharris2812

In this episode, I'm joined by Dr. Christine Funke, glaucoma surgeon and lead author of the Interventional Glaucoma Consensus Treatment Protocol, for a timely and practice-shaping conversation on the future of glaucoma management.We explore how interventional approaches are redefining the standard of care—shifting treatment earlier, improving consistency in clinical decision-making, and driving better outcomes for patients. Whether you're a clinician navigating evolving glaucoma strategies or a patient seeking clarity and confidence in your care, this conversation offers meaningful insight into where glaucoma treatment is headed next.

Imagine you are developing an idea for new research. You find a mountain of journal articles that seems perfect, but how can we process the vast amount of information, and how can we use it for our own research? Or imagine you need to synthesise 5 studies on “remote work productivity” for your next class on organisation research by tomorrow. In the past, this was a manual grind and involved a great deal of labour. While producing high-quality research remains a rigorous human endeavour, AI-powered literature review apps now allow you to synthesise insights more efficiently by having a conversation directly with the literature. We often talk about the “hype” versus the “real promise” of AI in management and social science. But how do we actually manage this? Today, I want to take you through three research engines that I've been exploring and using for quite some time: Elicit.com, Scite.ai, and Consensus. First, we will examine their specific functionalities—including recent advancements in agentic workflows and structured data extraction—to identify the unique purposes and benefits each tool offers to the researcher.Uncover even more insights and valuable information by visiting the blog profmanagement.de. Thank you for tuning in! If you enjoyed this episode, we'd be thrilled if you could leave us a glowing review on Apple Podcasts. Got a thought or opinion about this episode? Have a suggestion for a future topic? Send an audio file or voice note to hi@profmanagement.de. For all other comments, send us a tweet or DM at @profmanagement on Twitter or Instagram.

In this conversation, Rav and Loch Kelly explore the intersection of mindfulness and psychotherapy. They discuss practical steps for experiencing non-duality, the importance of integrating mindfulness with psychotherapy, and the role of agency and free will in personal development. Loch shares his personal journey into meditation and psychotherapy, highlighting the significance of understanding consciousness and the “true self.” The conversation emphasizes the need for a balanced approach to healing and enjoyment in life, and how different meditation methods can lead to various experiences. The discussion emphasizes the significance of living awake in the world, integrating spiritual practices into daily life, and making wise decisions from a place of authenticity and trust.Apple linkSpotify linkYouTube link(Available on all other podcast platforms too)Timestamps:00:00 – Intro00:59 – Who Is Loch Kelly?06:05 – How Meditation And Therapy Differ10:30 – Discovering Awareness Through Sport14:20 – Losing A Parent And Opening Up18:10 – Psychedelics And Consciousness Explained26:30 – Why Spiritual Bypass Causes Problems34:10 – When Meditation Fails Emotionally41:16 – Agency Free Will And Mental Health57:50 – What Is ‘The Self' In IFS01:23:00 – Noticing The Anxious Part01:27:30 – The Root Of Dissatisfaction01:36:30 – A Meditation01:48:30 – Why Pure Awareness Is Not Enough02:03:47 – Making Wise Decisions From The SelfI highly recommend you download Loch Kelly's ‘Mindful Glimpses' App here:https://lochkelly.org/mindful-glimpsesSupport The Illusion of Consensus!The Illusion of Consensus is a fully reader-supported publication. If you support the high-quality mental health and wellness journalism on this site, consider becoming a paid or founding member to receive exclusive articles, early-access episodes, and ask questions for future episodes. Or support The Illusion of Consensus with a one-time donation. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

Christian Brose, President and Chief Strategy Officer at Anduril Industries and author of The Kill Chain: Defending America in the Future of High-Tech Warfare, joins the show to talk about American industry and the future of war. ▪️ Times 02:26 Erosion of Military Advantage 11:11 The Nature of the Problem 16:42 Consensus and Urgency 21:01 Learning the Right Lessons in Ukraine 25:32 Scaling Up for the Offense 31:23 Leveraging AI for Defense 38:07 Will Liberal Arts and Humanities Win? 41:56 Arsenal-1 47:31 Silicon Valley and Defense 52:24 Collaborative Combat Aircraft Follow along on Instagram, X @schoolofwarpod, and YouTube @SchoolofWarPodcast Find more content on our School of War Substack

What happens when a historian who loves the American presidency is faced with a president like Donald Trump? We discuss the HBO documentary THE SOUL OF AMERICA (2020), about Joe Biden's favourite historian, Jon Meacham, as he struggles to make sense of the Trump era. Join us on Patreon for an extra episode every week - https://www.patreon.com/michaelandus "The Man Who Loved Presidents" by Thomas Frank - https://harpers.org/archive/2021/07/jon-meacham-thomas-frank-soul-of-america/ "The End of Resistance History" by Charlotte E. Rosen - https://proteanmag.com/2025/01/20/the-end-of-resistance-history/ "The Fight for the Four Freedoms" by Harvey J. Kaye - https://www.simonandschuster.ca/books/The-Fight-for-the-Four-Freedoms/Harvey-J-Kaye/9781451691443 "Take Hold of Our History" by Harvey J. Kaye - https://www.collectiveinkbooks.com/zer0-books/our-books/take-hold-of-our-history Our two previous episodes on Michael Moore Hates America (2004) https://soundcloud.com/michael-and-us/episode-8-michael-moore-hates-america https://www.patreon.com/posts/300-300th-61042533

CME credits: 0.25 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/ This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new guidance. Despite broad endorsement, many clinicians remain uncertain about applying the new framework. This activity aims to raise awareness, clarify updated criteria, and align practice with current evidence supporting earlier use of IL-23 and IL-17 inhibitors in appropriate patients.=

In this episode of Devolution Power Hour, Jon Herold and Chris Paul unpack the escalating psychological warfare playing out across media, politics, and the so-called conservative movement. The conversation moves through the coordinated infighting on display at AmFest, the push to manufacture consensus around preferred political successors, and the growing efforts to delegitimize President Trump from both inside and outside the movement. They examine how psyops operate by shaping perception rather than truth, using examples ranging from influencer politics and election narratives to Epstein-related distractions and foreign policy manipulation. The episode also explores emerging technology narratives, fusion energy announcements, Space Force milestones, and the deeper implications of parallel systems being built beneath the surface. Throughout, Jon and Chris emphasize discernment, personal sovereignty, and the importance of recognizing manipulation before choosing whether to engage or opt out entirely.

ROME VS. CARTHAGE: DESTINY, TRAGEDY, AND THE CONSENSUS FOR WAR Colleague Professor Edward J. Watts. The conflict between Rome and Carthage is symbolized by the tragedy of Dido, representing the incompatibility of their powers. Despite Hannibal's devastating victories, the Roman Republic prevailed through a political system that prioritized consensus and collective sacrifice, allowing them to endure immense losses without surrendering. NUMBER 11 1900 CARTHAGE

Rep. Lindsay Sabadosa: political and budget consensus?. by WHMP Radio

Turkel outlines his collaboration with US leaders, including Matt Pottinger and Nancy Pelosi, to secure sanctions and a formal genocide designation. He highlights the bipartisan consensus against Beijing's abuses, noting that his effective advocacy on the US Commission on International Religious Freedom led China to sanction him personally 1967 RED GUARD

Gov. Beshear talks about the state's budget shortfall, Democrats hold onto a seat in the Kentucky senate, Kentucky's Make America Healthy Again Task Force submits its policy recommendations, and a community theatre group in Barren County celebrates a big milestone.

Evolutionary psychologist Geoffrey Miller joins Rav on the Illusion of Consensus for a deep exploration of Gen Z's crisis of sex, dating, and relationships, unpacking why modern courtship is failing and how evolutionary instincts still shape today's mating market. Miller breaks down the rise of incel culture, the psychology of attraction, the impact of dating apps, and practical strategies young men can use to build confidence, social skills, and real-world romantic success. This conversation moves from societal trends to actionable insights on approaching women, navigating rejection, and understanding human mating psychology with clarity and honesty. A candid and highly informative session with Geoffrey Miller on how young people can thrive in a transformed romantic landscape.Follow Geoffrey on X: https://x.com/primalpolyTime-stamps: 00:00 – Intro05:55 – Queer Identity + Gen Z's Sexual Recession Unpacked13:25 – Sapiosexuals and Social Categories20:40 – What Intelligence Really Signals in Dating27:55 – Phones, Isolation, and the Collapse of Social Skills35:10 – Dating Apps and the New Mating Inequality42:25 – How Rejection Creates Modern Incel Psychology49:40 – Low-Stakes Flirting and Building Social Confidence56:55 – Approaching Women Without Creeping Them Out1:04:10 – Standards, Risk, and Smarter Short-Term Choices This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

Abdel is one of the most prolific developers in the Zero Knowledge space. Since our conversation in September, he was able to accomplish so much that he requested another interview to talk about it. So what happened with ZK STARKs that is so important? Time stamps: 00:01:04 Podcast Introduction & Sponsor Acknowledgments 00:02:15 Vlad's Rant on Bitcoin Media & Podcast Landscape 00:03:24 Bitcoin Takeover Podcast Mission & Seven-Year Anniversary 00:04:39 Transition to Abdel's Updates & ZK-STARKS 00:05:44 Abdel's Zcash & Bitcoin Proposals 00:07:00 Comparing Bitcoin and Zcash Community Reactions 00:08:36 Altcoins as Experimentation Grounds 00:11:23 Scaling, Rollups, and Drivechains 00:13:10 Abdel's Proposal for Native STARK Verification 00:17:19 Zcash's TDE and Layer 2 Possibilities 00:19:22 ZK-Rollups, Privacy, and Regulatory Pressures 00:21:02 Government Surveillance & KYC Concerns 00:24:26 Cultural Stigma Around Bitcoin Privacy 00:25:34 Zcash's SEC Presentation & Institutional Acceptance 00:28:58 Debate on Privacy, Transparency, and Backdoors 00:30:00 Bitcoin's Social Layer & Governance 00:32:47 Critique of Bitcoin Perfectionism & Altcoin Dismissal 00:35:49 Bitcoin's Mission: P2P Cash vs. Store of Value 00:36:49 Learning from Ethereum & Second-Layer Innovations 00:37:24 Sponsor Plugs & BTCfi Introduction 00:40:14 BTCfi: Bitcoin Staking & Yield Mechanisms 00:46:15 Bridging BTC to StarkNet & Atomic Swaps 00:48:36 BTCfi: KYC, Permissionless DeFi, and Institutional Offerings 00:50:59 DeFi Risks & Bitcoin Staking Security 00:51:40 ZK-STARK Verifiers on Bitcoin Cash 00:53:10 Bitcoin Cash, Zcash, and Social Layer Value 00:58:54 Bitcoin Cash's Technical Innovations & Community Dynamics 01:00:04 Quantum Resistance: Investor Fears & Satoshi's Coins 01:02:29 Quantum Threat Timeline & Migration Planning 01:10:25 Quantum-Resistant Signatures & Scalability Trade-offs 01:11:20 Hard Fork vs. Soft Fork for Quantum Resistance 01:13:08 Consensus, Confiscation Proposals, and Social Risks 01:17:56 Stagnation in Bitcoin Development & Altcoin Innovation 01:23:12 Ethereum's Role in Crypto Ecosystem 01:25:24 Zcash's Dual Incentives & Institutional Recognition 01:28:08 Zcash's Future: Innovation vs. Ossification 01:30:39 Sponsor Plugs: Noones & SideShift 01:33:42 Quantum Resistance Migration: Hard Fork Efficiency 01:37:11 Bitcoin's Future: Security, Consensus, and Upgrades 01:43:09 Bull Markets, Technological Breakthroughs, and Lightning 01:45:18 Lightning's Shift to B2B & Retail Challenges 01:47:02 Bitcoin Treasury Companies & Business Models 01:49:18 Seinfeld Analogy & Bitcoin's Societal Impact 01:52:11 Magic Wand: Abdel's One Change for Bitcoin 01:54:03 Legitimate Altcoins & Project Criteria 01:57:16 Monero, Kaspa, Litecoin, and Altcoin Usefulness 02:02:06 ZK-STARKs: Complementary or Standard? 02:06:21 ZK-STARKs for Fast Bitcoin Syncing 02:10:27 Call for Wallet Integration & User Experience 02:14:08 Bull Bitcoin Wallet & Open Source Security 02:22:02 Freedom Tech, Nostr, and ZK for Sovereignty 02:26:02 ZK-STARKs: Career Opportunities & Verification 02:28:41 Outro & Listener Easter Egg

Part of the BJUI/BURST podcast series In this BJUI/BURST podcast Mr Amgad Elmadani, who is a Urology Registrar in the UK with a passion for evidence-based practice, quality improvement, and medical education, discusses the British Association of Urological Surgeons Consensus document for the management of male genital emergencies: priapism. Read the consensus document here: https://bjui.pub/BAUS-priapism-consensus

In this week's Healthcare Preview, Debbie Curtis and Rodney Whitlock join Julia Grabo to discuss what they are watching on the House floor this week.

Who would be a policymaker right now? The list of economic problems that we need to solve ranges from “very difficult” to “existential”. An ambitious new book collects the ideas of many influential economists on how to approach these challenges. But can it avoid the mistakes of previous attempts to find an economic policy consensus? Andrés Velasco and Tim Besley are two of the editors of The London Consensus. Tim Phillips joined them at The London School of Economics to ask why the book was created, how policymakers can use it, and whether we should be wary of economists bearing paradigms. Download The London Consensus. https://www.lse.ac.uk/school-of-public-policy/research/london-consensus

China says its policy continuity and stable growth will provide certainty for the global economy, as there's a growing consensus that its prospects are positive (01:10). Beijing again denounces the Japanese prime minister's remarks over the Taiwan region (10:53). Ukraine presents the U.S. with an updated version of the peace plan proposed by Washington, while Russia says it wants agreements for lasting and sustainable peace with security guarantees for all involved (24:22).

Agenda: https://github.com/ethereum/pm/issues/1825

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Our Head of Research Product in Europe Paul Walsh and Chief European Equity Strategist Marina Zavolock break down the key drivers, risks, and sector shifts shaping European equities in 2026. Read more insights from Morgan Stanley.----- Transcript -----Paul Walsh: Welcome to Thoughts on the Market. I'm Paul Walsh, Morgan Stanley's Head of Research Product in Europe.Marina Zavolock: And I'm Marina Zavolock, Chief European Equity Strategist.Paul Walsh: And today – our views on what 2026 holds for the European stock market.It's Tuesday, December 9th at 10am in London.As we look ahead to 2026, there's a lot going on in Europe stock markets. From shifting economic wins to new policies coming out of Brussels and Washington, the investment landscape is evolving quite rapidly. Interest rates, profit forecasts, and global market connections are all in play.And Marina, the first question I wanted to ask you really relates to the year 2025. Why don't you synthesize your, kind of, review of the year that we've just had?Marina Zavolock: Yeah, I'll keep it brief so we can focus ahead. But the year 2025, I would say is a year of two halves. So, we began the year with a lot of, kind of, under performance at the end of 2024 after U.S. elections, for Europe and a decline in the euro. The start of 2025 saw really strong performance for Europe, which surprised a lot of investors. And we had kind of catalyst after catalyst, for that upside, which was Germany's ‘whatever it takes' fiscal moment happened early this year, in the first quarter.We had a lot of headlines and kind of anticipation on Russia-Ukraine and discussions, negotiations around peace, which led to various themes emerging within the European equities market as well, which drove upside. And then alongside that, heading into Liberation Day, in the months, kind of, preceding that as investors were worried about tariffs, there was a lot of interest in diversifying out of U.S. equities. And Europe was one of the key beneficiaries of that diversification theme.That was a first half kind of dynamic. And then in the second half, Europe has kept broadly performing, but not as strongly as the U.S. We made the call, in March that European optimism had peaked. And the second half was more, kind of, focused on the execution on Germany's fiscal. And post the big headlines, the pace of execution, which has been a little bit slower than investors were anticipating. And also, Europe just generally has had weak earnings growth. So, we started the year at 8 percent consensus earnings growth for 2025. At this point, we're at -1, for this year.Paul Walsh: So, as you've said there, Marina, it's been a year of two halves. And so that's 2025 in review. But we're here to really talk about the outlook for 2026, and there are kind of three buckets that we're going to dive into. And the first of those is really around this notion of slipstream, and the extent to which Europe can get caught up in the slipstream that the U.S., is going to create – given Mike Wilson's view on the outlook for U.S. equity markets. What's the thesis there?Marina Zavolock: Yeah, and thank you for the title suggestion, by the way, Paul of ‘Slipstream.' so basically our view is that, well, our U.S. equity strategist is very bullish, as I think most know. At this stage he has 15 percent upside to his S&P target to the end of next year; and very, very strong earnings growth in the U.S. And the thesis is that you're getting a broadening in the strength of the U.S. economic recovery.For Europe, what that means is that it's very, very hard for European equities to go down – if the U.S. market is up 15 percent. But our upside is more driven by multiple expansion than it is by earnings growth. Because what we continue to see in Europe and what we anticipate for next year is that consensus is too high for next year. Consensus is anticipating almost 13 percent earnings growth. We're anticipating just below 4 percent earnings growth. So, we do expect downgrades.But at the same time, if the U.S. recovery is broadening, the hopes will be that that will mean that broadening comes to Europe and Europe trades at such a big discount, about 26 percent relative to the U.S. at the moment – sector neutral – that investors will play that anticipation of broadening eventually to Europe through the multiple.Paul Walsh: So, the first point you are making is that the direction of travel in the U.S. really matters for European stock markets. The second bucket I wanted to talk about, and we're in a thematically driven market. So, what are the themes that are going to be really resonating for Europe as we move into 2026?Marina Zavolock: Yeah, so let me pick up on the earnings point that I just made. So, we have 3.6 percent earnings growth for next year. That's our forecast. And consensus – bottom-up consensus – is 12.7 percent. It's a very high bar. Europe typically comes in and sees high numbers at the beginning of the year and then downgrades through the course of the year. And thematically, why do we see these downgrades? And I think it's something that investors probably don't focus on enough. It's structurally rising China competition and also Europe's old economy exposure, especially in regards to the China exposure where demand isn't really picking up.Every year, for the last few years, we've seen this kind of China exposure and China competition piece drive between 60 and 90 percent of European earnings downgrades. And looking at especially the areas of consensus that are too high, which tend to be highly China exposed, that have had negative growth this year, in prior years. And we don't see kind of the trigger for that to mean revert. That is where we expect thematically the most disappointment. So, sectors like chemicals, like autos, those are some of the sectors towards the bottom of our model. Luxury as well. It's a bit more debated these days, but that's still an underweight for us in our model.Then German fiscal, this is a multi-year story. German fiscal, I mentioned that there's a lot of excitement on it in the first half of the year. The focus for next year will be the pace of execution, and we think there's two parts of this story. There's an infrastructure fund, a 500-billion-euro infrastructure fund in Germany where we're seeing, according to our economists, a very likely reallocation to more kind of social-related spend, which is not as great for our companies in the German index or earnings. And execution there hasn't been very fast.And then there's the Defense side of the story where we're a lot more optimistic, where we're seeing execution start to pick up now, where the need is immense. And we're seeing also upgrades from corporates on the back of that kind of execution pickup and the need. And we're very bullish on Defense. We're overweight the issue for taking that defense optimism and projecting out for all of Europe is that defense makes up less than 2 percent of the European index. And we do think that broadens to other sectors, but that will take years to start to impact other sectors.And then, couple other things. We have pockets of AI exposure in the enabler category. So, we're seeing a lot of strength in those pockets. A lot of catch up in some of those pockets right now. Utilities is a great example, which I can talk about. So, we think that will continue.But one thing I'm really watching, and I think a lot of strategists, across regions are watching is AI adoption. And this is the real bull case for me in Europe. If AI adoption, ROI starts to become material enough that it's hard to ignore, which could start, in my opinion, from the second half of next year. Then Europe could be seen as much more of a play on AI adoption because the majority of our index is exposed to adoption. We have a lot of low hanging fruit, in terms of productivity challenges, demographics, you know, the level of returns. And if you track our early adopters, which is something we do, they are showing ROI. So, we think that will broaden up to more of the European index.Paul Walsh: Now, Marina, you mentioned, a number of sectors there, as it relates to the thematic focus. So, it brings us onto our third and final bucket in terms of what your model is suggesting in terms of your sector preferences…Marina Zavolock: Yeah. So, we have, data driven model, just to take a step back for a moment. And our model incorporates; it's quantum-mental. It incorporates themes. It incorporates our view on the cycle, which is in our view, we're late cycle now, which can be very bullish for returns. And it includes quant factors; things like price target, revisions breadth, earnings revisions breadth, management sentiment.We use a Large Language Model to measure for the first time since inception. We have reviewed the performance of our model over the last just under two years. And our top versus bottom stocks in our model have delivered 47 percent in returns, the top versus bottom performance. So now on the basis of the latest refresh of our model, banks are screening by far at the top.And if you look – whether it's at our sector model or you look at our top 50 preferred stocks in Europe, the list is full of Banks. And I didn't mention this in the thematic portion, but one of the themes in Europe outside of Germany is fiscal constraints. And actually, Banks are positively exposed to that because they're exposed to the steepness – positively to the steepness – of the yield curve.And I think investors – specialists are definitely optimistic on the sector, but I think you're getting more and more generalists noticing that Banks is the sector that consistently delivers the highest positive earnings upgrades of any sector in Europe. And is still not expensive at all. It's one of the cheapest sectors in Europe, trading at about nine times PE – also giving high single digit buyback and dividend yield. So that sector we think continues to have momentum.We also like Defense. We recently upgraded Utilities. We think utilities in Europe is at this interesting moment where in the last six months or so, it broke out of a five-year downtrend relative to the European index. It's also, if you look at European Utilities relative to U.S. Utilities – I mentioned those wide valuation discounts. Utilities have broken out of their downtrend in terms of valuation versus their U.S. peers. But still trade at very wide discounts. And this is a sector where it has the highest CapEx of any sector in Europe – highest CapEx growth on the energy transition. The market has been hesitant to kind of benefit the sector for that because of questions around returns, around renewables earlier on. And now that there's just this endless demand for power on the back of powering AI, investors are more willing to benefit the sector for those returns.So, the sector's been a great performer already year to date, but we think there's multiple years to go.Paul Walsh: Marina, a very comprehensive overview on the outlook for European equities for 2026. Thank you very much for taking the time to talk.Marina Zavolock: Thank you, Paul.Paul Walsh: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

Chris Verrone, Head of Technical and Macro Research at Strategas, joins Double Take to unpack what investors should watch heading into 2026 — where consensus could break and how to position for the risks and opportunities.

In this week's episode, Joe and Lauri sit down to unpack the Dragula Titans Season 2 reunion—well… eventually. The reunion itself gets about ten minutes of focused airtime; the rest is pure Joe-and-Lauri chaos: bathroom disasters, awkward restaurant cats, questionable comedians, First Amendment weirdos, and one very dramatic microphone collapse. If you come for the Dragula analysis, stay for the unhinged tangent festival that only these two can deliver. Joe and Lauri agree that this reunion is better than most Dragula reunions… but still mostly a retread of old drama. The Dollya vs. the Cast confrontation sparks most of the meaningful discussion—though the Boulets' editing muddies the waters and leaves major context unexplained. The show revisits the Loris bathtub incident, but the evidence shown doesn't match the accusations levied against Dollya. Lauri notes the frustration of Dollya apologizing while the show cuts away to a separate conversation, leaving viewers without clarity. Eva's “I'll support you but from very far away” energy prompts a bigger conversation about loyalty and self-preservation among the cast. Cynthia vs. Blackberry gets rehashed, with Lauri pointing out Cynthia's selective outrage and how the logic of gameplay gets conveniently ignored. Joe observes that drag, an inherently solitary art form, doesn't always translate well to group competition—and the reunion makes that painfully clear. Consensus: great drag queens, complicated people, and a reunion that proves almost no one has changed their position since filming. A good hour of the episode is not about Dragula at all—and it's glorious. Lauri recounts accidentally blocking a mobility-impaired woman from the accessible stall, panicking, fleeing, and hiding in another restroom for ten minutes so she wouldn't have to face her. Joe immediately relates with his own “handicap seat anxiety” from the Alamo Drafthouse era. Joe updates Lauri on the search for a Christmas party venue that won't unleash a stray cat upon her.Spoiler: every promising venue apparently comes with two cats. Lauri suggests she'd rather dine among “roaming homeless men” than roaming cats. The two dig into a viral clip of a woman confronting a man over racist online comments. Lauri, horrified and impressed, wonders what possesses people to act with such intense malice online. Joe walks Lauri through the bizarre world of people who film grocery store entrances to provoke strangers into reacting on camera. A long reminiscence on: Comedians who police other comedians' material Possums falling from trees Robin Williams' unconscious joke absorption Why Lauri hates hanging out after shows A petty-cash scandal that once destroyed one of Joe's friendships Joe's microphone literally detaches mid-episode. Lauri vamped so hard she nearly passed out trying to fill dead air. The video may one day see the light of day. (No runway this week — no Ghost Host segment for reunion episodes.) Ultimately, the reunion offered: Some clarifications Some contradictions And a whole lot of cast members who still don't like each other But the real heart of the episode is Joe and Lauri spiraling into stories, ethics debates, comedy war stories, possum trauma, and moral hypotheticals about whether Lauri would turn Joe in for a crime (answer: immediately). Email: hellouglies@afterthought.mediaInstagram: @afterthoughtmediaSupport the shows: patreon.com/afterthoughtmedia Hosted by Joe Betance & Lauri Kay RoggenkampProduced and edited by Afterthought Media Learn more about your ad choices. Visit podcastchoices.com/adchoices

Rex Galbraith has worn almost every sales hat over his 20+ year SaaS career, and for the last decade, he's helped build Consensus into the category leader for interactive demo automation. In this episode, John and Rex dive deep into why traditional product demos are failing today's buyers—and what to do instead.You'll hear how Rex and his team use unideal customer profiles (UCPs) to actively disqualify bad-fit prospects, how automating parts of the demo process frees reps to sell smarter, not harder, and why focusing on retention over acquisition is the mindset shift modern sales orgs need.Rex also opens up about leading through tough moments—rebrands, layoffs, even running the company out of a grocery store—and the values that kept him grounded through it all. If you care about sales efficiency, buyer enablement, or becoming the kind of AE who thrives in the AI era, this one's for you.Are you interested in leveling up your sales skills and staying relevant in today's AI-driven landscape? Visit www.jbarrows.com and let's Make It Happen together!Connect with John on LinkedIn: https://www.linkedin.com/in/johnbarrows/Connect with John on IG: https://www.instagram.com/johnmbarrows/Check out John's Membership: https://go.jbarrows.com/pages/individual-membership?ref=3edab1 Join John's Newsletter: https://www.jbarrows.com/newsletterConnect with Rex on LinkedIn: https://www.linkedin.com/in/rexgalbraith Check out the Consensus Website: https://goconsensus.com/

For those asking, here is the overdue podcast release of my debate with Mark Cuban on Covid mandates. We've been aggressively prioritizing promotion of your YouTube channel this past month — something we haven't done before — and we unfortunately got behind on posting on podcast platforms. Moving forward, this will not be an issue. Enjoy the debate if you'd like to listen while driving or doing other activities! SummaryIn this conversation, Mark and I engage in a fiery debate about the COVID-19 pandemic, vaccine mandates, and the implications of free speech in academia. We explore the complexities of public health decisions, the perceived biases in academic discourse, and the evolving understanding of vaccine efficacy and safety. Mark defends the necessity of vaccine mandates for protecting public health, while I raise concerns about the adverse effects and the risk-benefit analysis for young people.—Spotify linkApple link(also available on Overcast and other platforms)—Chapters00:00 Diversity in Hiring: Merit vs. Representation21:11 The Efficacy of Vaccines and Community Health27:10 Vaccine Policies Across Europe33:19 Community Responsibility and Vaccination39:12 Myocarditis Risks and Vaccine Decisions47:06 Accountability for Vaccine Mandates52:40 Understanding Myocarditis Risks: Infection vs. Vaccine58:42 The Role of Comorbidities in COVID Outcomes01:04:01 Analyzing Risk: Vaccination vs. Natural Infection01:09:52 Community Benefit vs. Individual Risk in Vaccination—The Illusion of Consensus is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

Trudy Muscat of Deloitte Malta discusses Malta's changing international tax landscape, including its adoption of the two-pillar system and recently implemented transfer pricing rules. For more episodes from Lisbon, listen to:From Lisbon: The Search for Consensus on International TaxFrom Lisbon: The Future of International Tax CooperationFrom Lisbon: Portuguese Tax Administration in the Digital AgeFrom Lisbon: Highlights From the 2025 IFA CongressFor related tax news, read the following in Tax Notes:Bulgarian Parliament Approves Tax Treaty With MaltaEU's Tax Priorities Shift as Reform Stalls, Researchers SayMNE Profit Shifting Still Persistent, OECD Report Says***CreditsHost: David D. StewartExecutive Producers: Jeanne Rauch-Zender, Paige JonesProducers: Jordan Parrish, Peyton RhodesAudio Engineers: Jordan Parrish, Peyton Rhodes****Nominate someone for the Tax Analysts Award of Distinction in U.S. Federal Taxation! For more information, visit awards.taxanalysts.org. This episode is sponsored by Avalara. For more information, visit avalara.com. This episode is sponsored by Crux. For more information, visit cruxclimate.com/contact.

Het onvoorstelbare is gebeurd. Mark Zuckerberg grijpt in bij zijn favoriete hobbyproject. Metaverse krijgt, meldt persbureau Bloomberg, maar liefst 30 procent minder geld. Opvallend, want Zuckerberg roept al jarenlang dat dit dé toekomst is. Hij veranderde zelfs de naam van het bedrijf, omdat hij zo in de Metaverse gelooft.Dat lijkt nu dus anders te lopen. Hoe anders, dat zoeken we deze aflevering uit. Dan bekijken we ook de financiële puinhoop van dit hobyproject. Het heeft tot nu toe namelijk al 70 miljard dollar verloren.Hebben we het ook over een ander nieuwtje. Die komt van de journalisten van de Financial Times en gaat ook over Meta. Brussel gaat een onderzoek starten naar de AI-functies in Whatsapp.Jensen Huang hoeft president Trump niet te appen. De baas van Nvidia zag hem namelijk tijdens een lobbybezoek in Washington. Een belangrijk gesprek voor de toekomst van Nvidia. Verder hoor je meer over een cadeautje van president Trump aan de autosector. Hebben we het over de enorme koersval van Philips, de directie van Adidas dat een rechtszaak wint van de eigen aandeelhouders en de Amerikaanse arbeidsmarkt. Slecht nieuws: er worden heel veel Amerikanen ontslagen. Sinds 2020 niet zoveel als dit jaar.See omnystudio.com/listener for privacy information.

The push for a negotiated end to the nearly four-year war hit another stalemate this week, after a five-hour meeting in Moscow between U.S. Special Envoy Steve Witkoff, President Donald Trump's son-in-law Jared Kushner, and Russian President Vladimir Putin, ultimately producing no results. The Kremlin described the talks as constructive, but said compromises had not yet been found.Republican Matt Van Epps was projected to win a special election yesterday, to fill a vacant U.S. House of Representatives seat. Van Epps thanked Trump multiple times following his projected victory, padding the leader in the chamber heading into next year's midterm elections. Van Epps is a former commissioner of the Tennessee Department of General Services, and defeated Democratic opponent, state Representative Aftyn Behn.President Trump held his ninth Cabinet meeting of the year on Tuesday, as scrutiny grows over a deadly boat strike in the Caribbean. Some lawmakers claim Secretary of War Pete Hegseth ordered a second strike that killed two survivors, calling it a war crime. Hegseth denies it, saying Admiral Frank Bradley made the call and that it was the right decision under the “fog of war.” Trump defended the strikes, saying they saved hundreds of thousands of American lives, and warned that land strikes on cartels are coming soon, not just in Venezuela, but in any country sending illicit drugs into the U.S.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SGD865. CME/MOC/EBAC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2026.Charting New Paths in the Treatment of ER+, HER2- MBC: Seeking Clarity and Consensus Through Evidence-Aligned Clinical Cases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SGD865. CME/MOC/EBAC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2026.Charting New Paths in the Treatment of ER+, HER2- MBC: Seeking Clarity and Consensus Through Evidence-Aligned Clinical Cases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Announcing the Consensus EasyA Hackathon with EasyA Co-Founders Dom and Phil Kwok. EasyA Co-Founders Dom and Phil Kwok join CoinDesk's Sam Ewen to share how to participate in the Consensus EasyA Hackathon in Hong Kong this February. Plus, they unveil what industry leaders are looking for in winning projects, from technical skill and compelling narratives to the ideal co-founder team makeup. - Break the cycle of exploitation. Break down the barriers to truth. Break into the next generation of privacy. Break Free. Free to scroll without being monetized. Free from censorship. Freedom without fear. We deserve more when it comes to privacy. Experience the next generation of blockchain that is private and inclusive by design. Break free with Midnight, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠midnight.network/break-free⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - Need liquidity without selling your crypto? Take out a ⁠⁠⁠⁠⁠⁠Figure Crypto-Backed Loan⁠⁠⁠⁠⁠⁠, allowing you to borrow against your BTC, ETH, or SOL with 12-month terms and no prepayment penalties. They have the lowest rates in the industry at 8.91%, allowing you to access instant cash or buy more Bitcoin without triggering a tax event. Unlock your crypto's potential today at Figure! ⁠⁠⁠⁠⁠⁠https://figuremarkets.co/coindesk⁠⁠⁠⁠⁠⁠ - This episode was hosted by Sam Ewen.

THE BALLER LIFESTYLE PODCAST — EPISODE 603 Hosted by: Brian Beckner & Ed Daly Support the show: patreon.com/theballerlifestylepodcast FULL SHOW NOTES (APPLE PODCAST COMPREHENSIVE EDITION) Cold Open / Welcome Back Brian returns with Episode 603 of TBLS and immediately shouts out the Patreon crew—home of Bonus Bri, emotional sobriety updates, and all the private crying he refuses to do in public. Ed Daly joins and promptly delivers breaking news about an NFL player suspended for watching porn in a team meeting… at full volume. Chaos ensues. Thanksgiving Recap & Tea Talk Brian discovers green tea and is suddenly a Tea Guy. Ed forgets his tea entirely and feels betrayed. Listener debate begins: Should grown adults realistically be drinking gravy more than once a year? (The answer is apparently controversial.) ️ Woke Up Gay Again Mug Saga Brian receives a custom “Woke Up Gay Again” mug—plus his very own “gay card”—leading to: His daughter roasting him into dust. White pants discourse. Questions about whether the mug should be kept in his wallet for emergency resuscitation. ToeCutter strikes again. RIP Segment The boys honor (and roast) the deceased: Lynn Hamilton (Sanford & Son) Grandma the Galápagos Tortoise – lived 141 years, witnessed centuries of atrocities, said nothing. Randy Jones (Padres Cy Young winner, patron saint of 70s brown-and-yellow uniforms) Fuzzy Zoeller (apparently not 97 years old, though he looked it since 1997) ️ / Sports News Browns DL Shelby Harris calls 49ers WR Jauan Jennings a “hoe” And he clarifies it. Repeatedly. Patrick Beverley accused of punching and choking his teenage sister The guys discuss: Pat Bev's history of talking more than he plays The creepiness of men policing teenage girls' sex lives Whether Jay Stew thinks athletes should have podcasts (spoiler: he doesn't) Pickleball vs. Carmel, CA Carmel considers banning pickleball because it's “too noisy.” Brian rants about temporary courts, olds blowing Achilles tendons, and why tennis is superior. Drake Maye Spotted at His Girlfriend's Adult Cheer Competition Wait—adult cheer competitions? The guys spiral into: When activities should end What counts as “aging gracefully” The disturbing traditions of Texas A&M (midnight yell practice, dungarees, kick routines) Listener Voicemails & Mailbag Ben Astounded that Brian & Ed only consume gravy once a year. Matthew Richards Asks if Ed would peek at Hitler's infamous micro-penis if gifted a time machine. (Consensus: obviously yes.) Gfish Offers to file a complaint against Jay Stew's online bullies. Toe Cuttter Sends physical mail (!) including the mug and gay card, then demands: “Loudest Comer” rankings More show minutes A commitment to being “as gay as we want to be” Loudest Comer Power Rankings Chris Farley > John Belushi Dick Vitale > Harry Caray Air Bud Cinematic Universe: likely the evil clown, not Air Bud himself David Silver's mom (90210) receives an honorable mention Non-Sports: Weird News, Sexual Disasters & Political Horrors Hitler Micro-Penis Discourse Time travel urinal etiquette. Historical dick analysis. Rasputin's jar-encased hog. RFK Jr. Felching Poetry Scandal Brian & Ed read actual RFK sext-poems involving: “Harvests” “Canyons” “Don't spill a drop” Full-on National Institute of Health–certified felching definitions Listeners are begged to call in if they've ever actually felched (unlikely, but we're listening). UK Man Hospitalized After Eating 7 Pounds of Gummy Cola Bottles Relatable to a point. Then horrifying. Hugh Hefner reportedly drank 20 Pepsis a day + 3 lbs of M&Ms The true cause of Playboy longevity? Macaulay Culkin legally changes his middle name to Macaulay Culkin The poll results are honored. Italian Man Dresses as Dead Mother to Collect Pension Mrs. Doubtfire but make it mortifying. Smokey Robinson Accused of Forcing Strangers to Touch His Erection Brian plays tracks from GASMS, Smokey's actual album filled with sex songs to confirm: Yes, this man is capable of anything. SUPPORT THE SHOW Patreon subscribers get extended dong talk + bonus content weekly. Join here: patreon.com/theballerlifestylepodcast Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What would you do if your boss was actually a giant bug? Something to think about.Today we're talking about Sub-Verge by Interactive Tragedy, Limited! A game about listening to people and trying not to drown. Get Sub-Verge on Steam or itch.io. Follow Interactive Tragedy, Limited's work on their website!Links:Subtle Mind - A Sub-Verge prequel by Zach Dodson on Steam---Support us on Ko-fi!Visit our website!Follow us on Twitch!Follow the show on Bluesky!Check out The Worst Garbage Online!---Art by Tara CrawfordTheme music by _amaranthineAdditional sounds by BoqehProduced and edited by AJ Fillari---Timecodes:(00:00) - drop.zip (00:30) - Interactive tragedy-likes (01:13) - What is Sub-Verge? (05:12) - There are multiple endings (05:59) - Trying to pick the right order (14:02) - The player can only decide who pulls (15:54) - What the game is "about" (17:56) - Spoilers (17:57) - The Mind (20:46) - How the story is doled out (22:27) - Krake 2025 (27:25) - Some friction (29:27) - High level story chat (34:06) - The endings (40:15) - The game is bleak! (42:29) - The game is good (44:32) - Big Takeaways (44:52) - Chase's Big Takeaway (51:46) - AJ's Big Takeaway (57:57) - A Noam Chomsky cliffhanger (58:17) - Thank you for listening

Important video message for subscribers of The Illusion of Consensus!As the founder and author of this Substack I've invested in some key areas to expand its reach and visibility on various platforms like YouTube and Instagram with new strategic hirees.In the last several months since Jay has left the Substack, there has been an understandable but challenging precipitous drop in paid memberships.As I take the podcast in a new direction with focus on mental health, wellness, relationships, social health etc I hope you'll support me in my mission of shattering mainstream consensus and providing you with the highest quality tools, knowledge, and information to improve your life (mentally, socially, relationally, spiritually etc).Upcoming guests:Bret Weinstein, Robert Malone, Mattias Desmet, Jonathan Pageau, and more.Please support us now (sale extended to Cyber Monday!):* 30% off a yearly subscription:* 50% off for 90 days of monthly subscription:Alternatively, if you'd like to make a larger, one-time donation the show, here is a link where you can do so:Thank you again for being part of this community. Wishing you a great weekend with family and friends. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

The Canadian consensus on immigration cratered last year. In the fall of 2024, an Environics poll found that for the first time in a quarter century most Canadians felt there was too much immigration. Under former prime minister Justin Trudeau, the country experienced one of the biggest periods of immigration growth in its history, but after the shift in public opinion, the Liberal government reversed course. Despite big reductions to immigration levels, most Canadians still think rates are too high.Today, The Decibel is looking at how Canada's relationship with immigration significantly changed, what it's meant for the country and the people who have immigrated to it, and where we go from here.Tony Keller, Globe columnist and author of Borderline Chaos: How Canada Got Immigration Right, and Then Wrong, will walk us through what motivated Trudeau's dramatic changes to the immigration system and how they impacted the country. And then, Rupa Banerjee, professor and Canada Research Chair in Economic inclusion, Employment and Entrepreneurship of Canada's Immigrants, will explain the effect that whiplash-like changes to the system have had on recent immigrants and our economy.Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Show Notes In this episode, Ernie discusses the impact of AI on the legal profession, emphasizing that while AI may replace surface-level tasks, the best lawyers will thrive by focusing on deeper, strategic thinking and understanding complex legal outcomes. Takeaways The best lawyers won't just survive this wave of AI. They're gonna dominate. If your work is mostly surface level, AI is gonna replace you. To remain indispensable, focus on outcomes and hidden risks. Understanding the chessboard of legal scenarios is crucial. Lawyers must evolve their skills to adapt to AI advancements. AI should be seen as a tool, not a replacement. Strategic thinking is key in the legal profession. The future of law requires innovation and adaptation. Surface-level tasks can be automated, but deeper insights cannot. Indispensable lawyers will thrive in the AI era. Resource Links ChatGPT Lab (a weekly AI workshop for lawyers) Apply to join the ChatGPT Lab The 80/20 Principle (my techlaw newsletter) The Inner Circle (my online community for lawyers) Follow and Review: I'd love for you to follow me if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. I'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select "Ratings and Reviews" and "Write a Review" then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast. Thanks to the sponsor: Smith.ai Smith.ai is an amazing virtual receptionist service that specializes in working with solo and small law firms. When you hire Smith.ai, you're hiring well-trained, friendly receptionists who can respond to callers in English or Spanish. And they have a special offer for podcast listeners where you can get an extra $100 discount with promo code ERNIE100. Sign up for a risk-free start with a 14-day money-back guarantee now (and learn more) at smith.ai.  

Juan Manuel Vázquez of Loyens & Loeff discusses the evolving international tax agenda, including ongoing pillar 2 negotiations and taxing the digital economy.For more episodes from Lisbon, listen to:From Lisbon: The Future of International Tax CooperationFrom Lisbon: Portuguese Tax Administration in the Digital AgeFrom Lisbon: Highlights From the 2025 IFA CongressFor related tax news, read the following in Tax Notes:G20 Leaders Affirm Goal for OECD Global Minimum Tax AccordIf Pillar 2 Directive Reopens, EU Won't Close It, Official SaysOECD Talks on U.S. Pillar 2 Exemption Focused on SimplificationItaly Defends DST and Urges OECD to Restart Digital Talks**This episode is sponsored by Avalara. For more information, visit avalara.com.***CreditsHost: David D. StewartExecutive Producers: Jeanne Rauch-Zender, Paige JonesProducers: Jordan Parrish, Peyton RhodesAudio Engineers: Jordan Parrish, Peyton Rhodes****Nominate someone for the Tax Analysts Award of Distinction in U.S. Federal Taxation! For more information, visit awards.taxanalysts.org.

“Even though the panelistswere huge aligner users, the statements are not so in favour of aligners, they are surprisingly reasonable.” “It's very difficult to find a real aligner experts without a conflict of interest. Almost impossible.” “If you explain the differences honestly, most of my extraction patients choose fixed appliances. I'm not selling aligners.” “Direct printing is the real breakthrough, but right now it has too many shortcomings to be a standard technology.” “I am pessimistic. We must fight for our profession — against the idea that technology can replace orthodontists.” In this episode, I'm joined by Vincenzo D'Antò, lead author and contributing author of this year's two major consensusstatements on clear aligners. We explore the key findings from these landmark papers and how they translate into real-world clinical practice. Vincenzo shares his own views on aligners, their limitations, and his pragmatic approach to integrating hybrid mechanics, particularly skeletal anchorage, into alignertreatment. We discuss recent innovations in aligner therapy, distinguishing those with genuine clinical value from those that are ineffective. We also hear Vincenzo's candid concerns about the future of orthodontics.  03:00 – Why did youcreate this Delphi aligner consensus?05:03 – How were thealigner experts selected for the study?06:51 – Do conflictsof interest affect aligner consensus statements?11:49 – Crowding: Whydoes the Alharfi 2025 SR show better outcomes for aligners?15:49 – 7 vs 10 vs 14days: How often should patients change aligners?20:03 – Are complexmovement failures a design flaw or inherent to aligners?22:19 – What trulylimits clear aligner biomechanics?25:46 – Is hybridorthodontics the future of predictable aligner treatment?29:35 – What hybridmechanics do you use most in practice?32:05 – Can wereliably treat extraction cases with aligners?36:03 – Is betterOHRQoL worth compromised occlusal outcomes?39:11 – Do alignerswork for growing patients, or is this just marketing?41:34 – Why ishigh-quality aligner research still so weak?44:30 – Final advice:What should orthodontists focus on for the future? Click on the link below to view previous episodes, to refresh topics,pick up tricks and stay up to date.  Please like and subscribe if you find it useful! Please visit the website for this interview podcast:https://orthoinsummary.com/is-there-really-a-consensus-on-aligners-a-delphi-author-explains-orthodontics-in-interview-vincenzo-danto/ Spotify podcasts for other platforms YouTubehttps://youtu.be/jpMUbYINxzg #OrthodonticsInSummary#VINCENZOD'ANTO#Orthodontics#ClearAligners#AlignerTherapy#HybridOrthodontics#SkeletalAnchorage#TADs#OrthodonticEvidence#OrthodonticsInInterview#FarooqAhmed#VincenzoDAnto#OrthodonticBiomechanics#OrthodonticResearch  Farooq Ahmed

Detroit Lions Podcast: OT Draft Fits for the Lions November Draft Lens From the Detroit Lions Podcast It is late November and the Detroit Lions conversation already includes the NFL Draft. Playoff expectations sit high, but roster building never sleeps. The focus here is offensive tackle. Four names came up. Three look like fits for Detroit. One does not. Two earned deep dives, and both would impact the trenches in different ways. The Lions value athletic thresholds, positional movement skills, and verified testing. Measurements matter. So does tape that shows recovery, spatial control, and finish. Day 1 versus Day 2 will hinge on those numbers. Early Day 2 is a sweet spot if the board and need align. Brad Holmes has shown a willingness to maneuver when a specific player matches the profile. Caleb Tiernan's Decker-Style Fit at Left Tackle Caleb Tiernan of Northwestern checks boxes that tie directly to Taylor Decker's role. He is a left tackle with real experience and Detroit roots at Country Day. He carries a big frame at six foot seven and 329 pounds. The size looks honest. The game reflects it. Tiernan is not the smoothest mover, but he is coordinated and functional. He gets into space, engages, and finishes. He uses his length well and fires his hands with improving placement. If he loses early, he knows how to recover. That ability shows on film and matters on Sundays. The profile reads leader with grit and snarl. The style echoes Decker's steady control more than twitchy flash. On consensus boards he sits near 62. On a sharper internal board he ranks 39. That places him squarely in the second round. For the Detroit Lions, that screams early Day 2 consideration. It might be earlier than their natural slot, which invites the familiar question about moving up. Athletic testing will be important. He is the least athletic of the discussed quartet, but not a bad athlete. If the numbers clear Detroit's benchmarks, the fit stays strong. Blake Miller's Surge and a Right Tackle Contrast Blake Miller of Clemson brings a different energy. A four-year starter at right tackle with a small taste of left tackle, he is an ascending talent. The tape this season is the best he has played. Footwork pops. Hips and shoulders sync. He keeps his feet alive and wins in space. He seals corners. He down blocks with force. The athletic profile is real and functional in the open field. Miller's arc shifted from a summer fifth or sixth round projection to a top-20 grade on that same internal board. Consensus has him near 65. The weight is the pivot. He was listed at 295 in spring. He is pushing 300 now. If he hits 305 to 310 by the combine, first round is on the table. The style differs from Penei Sewell. Miller is more speed and space than pure power. That contrast can work in Detroit's ecosystem. Two tackles. Two lanes to upgrade depth and plan succession. As the Detroit Lions press forward, the offensive line remains the identity. The draft will offer answers at left tackle and right tackle. The board already hints at where to look. #DetroitLions #Lions #DetroitLionsPodcast #CalebTiernan #BlakeMiller #TaylorDecker #PeneiSewell #LeftTackle #RightTackle #EarlyDay2 #FirstRoundOnTheTable #AthleticThresholds #PositionalMovementSkills Learn more about your ad choices. Visit megaphone.fm/adchoices

In this rich conversation, Camden Bucey sits down with Dr. Chad Van Dixhoorn—historian, pastor, and professor at Reformed Theological Seminary in Charlotte—to explore the remarkable work and enduring wisdom of the Westminster Assembly. Together, they discuss how the divines pursued theological clarity through collaboration, not compromise, and how their humility and respect shaped confessional standards that have guided the Reformed church for centuries. Van Dixhoorn explains why the Westminster Confession should be seen as "a document with compromises, not a compromise document," how its chapters differ in tone and theological armor, and what this teaches us about confessional fidelity today. The conversation also explores doctrinal preaching—how to preach theology without losing the text—and why confessions must unite rather than constantly be rewritten. With warmth and clarity, Dr. Van Dixhoorn reminds us that Reformed unity is not built on uniformity, but on the shared pursuit of truth before the face of God. 00:00 Introduction and Word & Deed Ministry 01:18 At the Reformation and Worship Conference 04:10 Introducing Dr. Chad Van Dixhoorn and the Westminster Assembly 06:00 Consensus, Collaboration, and Compromise in the Assembly 09:30 The Process of Drafting the Westminster Standards 12:00 Respectful Debate and the Spirit of the Divines 19:30 Comparing the Westminster and Heidelberg Traditions 25:30 Confessional Revision, Study Committees, and Doctrinal Reports 33:00 Doctrinal Preaching: From Text to Theology 40:50 The Joy of Teaching and Ongoing Research on the Divines

In this rich conversation, Camden Bucey sits down with Dr. Chad Van Dixhoorn—historian, pastor, and professor at Reformed Theological Seminary in Charlotte—to explore the remarkable work and enduring wisdom of […]

Announcing Consensus x SALT Hong Kong Institutional Summit. Consensus and SALT are teaming up to host an Institutional Summit in Hong Kong. This closed-door gathering is designed for sophisticated investors and capital allocators, focusing on constructive debates and providing key insights for deploying capital into the digital asset class. Consensus Chairman Michael Lau and SALT CEO John Darsie join CoinDesk's Jennifer Sanasie to preview the event. Learn more about the Summit here. - Break the cycle of exploitation. Break down the barriers to truth. Break into the next generation of privacy. Break Free. Free to scroll without being monetized. Free from censorship. Freedom without fear. We deserve more when it comes to privacy. Experience the next generation of blockchain that is private and inclusive by design. Break free with Midnight, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠midnight.network/break-free⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - Need liquidity without selling your crypto? Take out a ⁠Figure Crypto-Backed Loan⁠, allowing you to borrow against your BTC, ETH, or SOL with 12-month terms and no prepayment penalties. They have the lowest rates in the industry at 8.91%, allowing you to access instant cash or buy more Bitcoin without triggering a tax event. Unlock your crypto's potential today at Figure! ⁠https://figuremarkets.co/coindesk⁠ - Genius Group has partnered with CoinDesk for Bitcoin Treasury Month, launching the Genius x CoinDesk Quest. Participants can join the Bitcoin Academy, complete free microcourses from experts like Natalie Brunell and Saifedean Ammous, and enter to win 1,000,000 GEMs (worth 1 BTC) promoting bitcoin education and adoption.Learn more at:  ⁠⁠⁠⁠⁠⁠⁠geniusgroup.ai/coindesk-bitcoin-treasury-month/⁠⁠⁠⁠⁠⁠⁠ - This episode was hosted by Jennifer Sanasie.

In October, President Trump and President Xi Jinping met for the first time in Trump's new presidential term. The meeting ended with commitments from both countries designed to lower trade tensions —– something many observers greeted with relief. But, according to Watson Senior Fellow and Director of the Watson School's China Initiative Lyle Goldstein, perhaps more noticeable was what was left out of this meeting; almost all of the pressing security issues that exist between the two countries, including the one Goldstein sees as the “most dangerous of all”– the U.S. relationship with Taiwan.On this episode, host Dan Richards speaks with Goldstein about the state of U.S.-China relations over Taiwan, why he believes this issue represents one of the world's greatest risks to human safety, and why now is the moment to reconsider the U.S. foreign policy consensus on this geopolitical flashpoint. Learn more about the Watson School's China InitiativeRead Lyle's multi-part series on the past, present, and future of US-China relationsTranscript coming soon to our website

FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet EP. # 1282 JFK & the X-Rays that Shatter the Official Story November 22, 1963 wasn't the day democracy died—it was the day it was murdered in plain sight and autopsied with criminal fraud. Physicist Dr. David Mantik returns to Strange Planet with explosive New EVIDENCE - optical density measurements of the original JFK autopsy X-rays, proving beyond doubt that the president's head wounds were surgically altered on film before the body ever reached Bethesda. And, Cold War historian Walter Herbst reveals how the assassination wasn't chaos, but consensus policy born from covert operations and geopolitical necessity. This is the original Deep State “deep-fake”—forged evidence that still controls the narrative today. GUESTS: Dr. David Mantik, MD, PhD – A radiation oncologist and physicist who personally examined the JFK autopsy X-rays and photographs at the National Archives on nine separate occasions. Author of President John F. Kennedy: The Final Analysis, The JFK Assassination Decoded: Criminal Forgery in the Autopsy Photographs and X-Rays, and the groundbreaking new book JFK Was Killed by Consensus. His peer-reviewed optical density data proves the autopsy images were altered—making him the foremost forensic challenger to the official record. Walter Herbst – Cold War historian and author of the landmark two-volume series It Did Not Start With JFK, which traces the intelligence networks, propaganda machines, and Berlin/Cuba crises that made Kennedy's removal official—if unspoken—policy. His latest work, Last Resort Beyond Last Resort, exposes why the assassination guaranteed no second invasion of Cuba and protected NATO's flank in Berlin. Herbst doesn't peddle conspiracy theories; he documents the paper trail of the original Deep State in action. WEBSITES: https://www.facebook.com/WalterHerbstAuthor https://themantikview.org BOOKS: The Assassination of John F. Kennedy: The Finaly Analysis The JFK Assassination Decoded JFK was Killed by Consensus It Did Not Start with JFK Vols 1 & 2 Last Resort Beyond Last Resort SUPPORT OUR SPONSORS!!! FOUND – Smarter banking for your business Take back control of your business today. Open a Found account for FREE at Found dot com. That's F-O-U-N-D dot com. Found is a financial technology company, not a bank. Banking services are provided by Lead Bank, Member FDIC. Join the hundreds of thousands who've already streamlined their finances with Found. HIMS - Making Healthy and Happy Easy to Achieve Sexual Health, Hair Loss, Mental Health, Weight Management START YOUR FREE ONLINE VISIT TODAY - ⁠HIMS dot com slash STRANGE⁠ ⁠https://www.HIMS.com/strange⁠ MINT MOBILE Premium Wireless - $15 per month. No Stores. No Salespeople. JUST SAVINGS Ready to say yes to saying no? Make the switch at MINT MOBILE dot com slash STRANGEPLANET. That's MINT MOBILE dot com slash STRANGEPLANET ⁠BECOME A PREMIUM SUBSCRIBER!!!⁠ ⁠https://strangeplanet.supportingcast.fm⁠ Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit ⁠https://strangeplanet.supportingcast.fm⁠ Use the discount code "Planet" to receive $5 OFF off any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit ⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

In this episode the hosts dig into a $2.7 million EdTech business serving architects—$450K revenue, ~$227K profit, ~30 % growth—yet debate whether its 11.9× profit asking price makes any sense.Business Listing – https://app.acquire.com/startup/aUdw7lekR1TbMTB7h3oH00Of2KH2/9zqyExayXzwGmnlz6QWA?utm_medium=email&_hsenc=p2ANqtz-98r-wxCcPABDrP80rGNweSlNs2VkMvwGKxMByTIVyTIen9tvlCC_HRGTYrJ1hp08w7BlWcQs_9_6gkpNUKm734YYgaCg&_hsmi=386717396&utm_content=386717396&utm_source=hs_emailWelcome to Acquisitions Anonymous – the #1 podcast for small business M&A. Every week, we break down businesses for sale and talk about buying, operating, and growing them.

Stephan Livera and Kevin Cai dive into the Bitcoin spam debate, breaking down the different camps in the community, the line between consensus and policy, and how transaction filters, dust limits, and Libre Relay affect the network. They explore mining economics, fee dynamics, and the subjective nature of what people call spam.Kevin also discusses UTXO consolidation, decentralization, and how BRC-20 activity impacts the fee market. He explains the cultural differences behind spam opinions and the broader implications for Bitcoin's ecosystem.The conversation covers the challenges of Bitcoin development, including concerns around temporary fixes like RDTS, and why programmability matters for Bitcoin's future utility.Takeaways: